Cambridge, MA – Novartis has signed a collaboration agreement with clinical data network TriNetX giving its researchers access to real-time data to support clinical study and protocol design, site selection, and patient recruitment.
Novartis through its pharmaceutical division develops patent-protected medicines for commercialization in oncology, primary care and specialty care.
The TriNetX proprietary network includes healthcare providers, pharmaceutical companies and contract research organizations around the world, enabling researchers to locate patients at sites for clinical trials.
Available data includes demographic, diagnosis, procedure, medication, and laboratory test information. Analytics modules provide critical detail on the criteria and new patient rate.
Anonymized data can be traced to healthcare providers who identify individual patients, allowing researchers to develop virtual patients that share common characteristics for recapitulation in real world clinical trial settings.
“Our mission is to disrupt the clinical trial design space by unleashing the power of data that is currently locked away,” Gadi Lachman, TriNetX CEO, said. “Through our network, healthcare providers, pharma and contract research organizations can create strategic partnerships to improve clinical research and patient care.”
Lachman called the collaboration agreement with Novartis “a win-win” for the two companies, member institutions, and ultimately patients.
Novartis focuses its business on three divisions: pharmaceuticals, eye care and generics. The divisions are supported by the Novartis Institutes for BioMedical Research (NIBR) and a centralized services group to facilitate collaboration across divisions.
The NIBR network research institutes encourage teams and individuals to work across institutional and geographic boundaries, according to the company. NIBR is based in Cambridge, MA.
(Sources: TriNetX, Novartis)
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery
